Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her-2 Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01426880
What this trial is testing

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

Who this might be right for
Tubular Breast Cancer Stage IIMucinous Breast Cancer Stage IIBreast Cancer Female NOS+5 more
GBG Forschungs GmbH 595
Testing effectiveness (Phase 2)Study completedNCT02291913
What this trial is testing

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
SCRI Development Innovations, LLC 48
Testing effectiveness (Phase 2)Ended earlyNCT04675827
What this trial is testing

De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

Who this might be right for
HER2-positive Breast CancerER-Negative Breast CancerPR-Negative Breast Cancer+1 more
Jules Bordet Institute 139
Testing effectiveness (Phase 2)Looking for participantsNCT04683679
What this trial is testing

Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerBreast Cancer+1 more
Memorial Sloan Kettering Cancer Center 34
Large-scale testing (Phase 3)Study completedNCT01740427
What this trial is testing

Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

Who this might be right for
Breast Neoplasms
Pfizer 666
Testing effectiveness (Phase 2)Looking for participantsNCT05766410
What this trial is testing

Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC

Who this might be right for
Breast CancerHormone Receptor-positive Breast CancerHormone Therapy
National Taiwan University Hospital 60
Testing effectiveness (Phase 2)Looking for participantsNCT07796880
What this trial is testing

Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Who this might be right for
Hormone Receptor-Positive Breast CancerHER2 Low Breast CarcinomaEarly-Stage Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 80
Testing effectiveness (Phase 2)Study completedNCT00546156
What this trial is testing

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

Who this might be right for
Breast Cancer
Ian E. Krop, MD, PhD 104
Testing effectiveness (Phase 2)Looking for participantsNCT06525766
What this trial is testing

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen-receptor-positive Breast CancerMetastatic HER2-Negative Breast Carcinoma+1 more
Mayo Clinic 35
Testing effectiveness (Phase 2)Looking for participantsNCT05398861
What this trial is testing

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

Who this might be right for
HER-2 Negative Breast Cancer
Henan Cancer Hospital 79
Not applicableNot Yet RecruitingNCT07387861
What this trial is testing

PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study

Who this might be right for
Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Assiut University 70
Large-scale testing (Phase 3)Looking for participantsNCT07492641
What this trial is testing

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

Who this might be right for
HR+/HER2- Breast Cancer
BeOne Medicines 1,056
Testing effectiveness (Phase 2)UnknownNCT05927779
What this trial is testing

Study of TFX06 in Women With Advanced Breast Cancer.

Who this might be right for
ER+, HER2- Advanced Breast CancerMetastatic Breast Cancer
Zhejiang Yangli Pharmaceutical Technology Co., Ltd. 74
Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Early research (Phase 1)Study completedNCT01245205
What this trial is testing

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+4 more
National Cancer Institute (NCI) 28
Large-scale testing (Phase 3)Not Yet RecruitingNCT07406542
What this trial is testing

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Who this might be right for
Recurrent or Metastatic Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd. 400
Testing effectiveness (Phase 2)Active Not RecruitingNCT03789110
What this trial is testing

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 30
Testing effectiveness (Phase 2)Looking for participantsNCT06827613
What this trial is testing

Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerHR+, HER2-, Advanced Breast Cancer
Marengo Therapeutics, Inc. 50
Early research (Phase 1)WithdrawnNCT06229392
What this trial is testing

Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer

Who this might be right for
Breast CancerBreast Cancer Triple Negative
Rush University Medical Center
Large-scale testing (Phase 3)WithdrawnNCT03081234
What this trial is testing

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals
Next Page